Treating atopic dermatitis with IgE antagonists
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 20, 2002
app pub date -
Nov 19, 2001
filing date -
Jan 29, 1998
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to a composition for treatment of atopic dermatitis comprising a suitable IgE antagonist that does not induce the release of mediators of allergy; for example, anti-IgE antibodies that bind to secreted IgE, membrane IgE on the surface of IgE-producing B cells, but not to IgE bound to the Fc.epsilon.RI on the surface of basophils or mast cells. Preferably, these antibodies also do not bind to IgE bound to Fc.epsilon.RII receptors. It is also preferable if these antibodies have human IgG1 or IgG3 constant regions, as well as further human portions, if desired. The composition can be administered systemically or topically.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully